Plasma thymidine kinase 1 activity and outcome of ER+ HER2− metastatic breast cancer patients treated with palbociclib and endocrine therapy

202028 citationsJournal Articlegold Open Access

Authors

Luc Cabel · Université de Versailles Saint-Quentin-en-Yvelines

Dan Rosenblum · Institut Curie

Florence Lerebours · Institut Curie

Etienne Brain · Institut Curie

Delphine Loirat · Institut Curie

Mattias Bergqvist · Biovica (Sweden)

Paul Cottu · Institut Curie

Abstract

This study demonstrates the clinical validity of pTKa as a new circulating prognostic marker in ER+/HER2- MBC patients treated with endocrine therapy and palbociclib.

Topics & Keywords

Advanced Breast Cancer Therapies Chronic Lymphocytic Leukemia Research Cancer-related Molecular Pathways

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Breast Cancer Research

Volume 22, Issue 1, pp. 98-98

DOI: 10.1186/s13058-020-01334-2

Field-Weighted Citation Impact: 2.03